Apatinib and Etoposide Capsule Versus Weekly Paclitaxel in Patients With Platinum Resistant Ovarian Cancer
The study is conducted to evaluate the efficacy, safety and tolerability of apatinib (375 mg qd) and etoposide capsule (50 mg/d, d1-14, q3w) in subjects with platinum resistant or refractory ovarian cancer compared with weekly paclitaxel (80 mg/m2, d1, d8, d15, q3w).
Ovarian Cancer
DRUG: Apatinib|DRUG: Etoposide|DRUG: Paclitaxel
Progression free survival(PFS) by independent review committee(IRC), PFS was defined as the time from the date of randomization to the first documented disease progression or death, whichever occurred first. Progression was based on tumor assessment made by the IRC according to the RECIST criteria, up to approximately 2 years
The incidence and severity of adverse events (AEs) and serious adverse events (SAEs), Frequency and severity of Adverse Events or Serious Adverse Events as defined by CTCAE version 5.0, up to approximately 2 years|PFS by investigator, PFS was defined as the time from the date of randomization to the first documented disease progression or death, whichever occurred first. Progression was based on tumor assessment made by the investigator according to the RECIST criteria, up to approximately 2 years|Objective Response Rate (ORR), Proportion of subjects who have a complete or partial response relative to baseline as assessed per RECIST 1.1 criteria as well as Gynecologic Cancer Intergroup (GCIG) cancer antigen (CA)-125 criteria., up to approximately 2 years|Overall Survival (OS), OS is the time interval from the date of randomization to death from any cause., up to approximately 3 years|EQ-5D-5L questionnaire, EQ-5D-5L is a questionnaire that focus on issues specific to ovarian cancer., up to approximately 2 years|FOSI-8 questionnaire, FOSI-8 is a questionnaire that focus on issues specific to ovarian cancer., up to approximately 2 years
The study is conducted to evaluate the efficacy, safety and tolerability of apatinib (375 mg qd) and etoposide capsule (50 mg/d, d1-14, q3w) in subjects with platinum resistant or refractory ovarian cancer compared with weekly paclitaxel (80 mg/m2, d1, d8, d15, q3w).